PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Anebulo Pharmaceuticals, Inc. (ANEB)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS0345691036
CUSIP034569103
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$64.83M
EPS-$0.41
Year Range$1.62 - $4.05
Target Price$6.00
Short %0.08%
Short Ratio0.56

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ANEB

Anebulo Pharmaceuticals, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Anebulo Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-80.00%-60.00%-40.00%-20.00%0.00%20.00%OctoberNovemberDecember2024FebruaryMarch
-59.58%
24.14%
ANEB (Anebulo Pharmaceuticals, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Anebulo Pharmaceuticals, Inc. had a return of 18.60% year-to-date (YTD) and 3.24% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date18.60%10.16%
1 month5.51%3.47%
6 months-5.28%22.20%
1 year3.24%30.45%
5 years (annualized)N/A13.16%
10 years (annualized)N/A10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20246.40%5.63%
202329.17%9.50%-27.99%3.64%6.14%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Anebulo Pharmaceuticals, Inc. (ANEB) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ANEB
Anebulo Pharmaceuticals, Inc.
-0.01
^GSPC
S&P 500
2.79

Sharpe Ratio

The current Anebulo Pharmaceuticals, Inc. Sharpe ratio is -0.01. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00OctoberNovemberDecember2024FebruaryMarch
-0.01
2.79
ANEB (Anebulo Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Anebulo Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-67.93%
0
ANEB (Anebulo Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Anebulo Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anebulo Pharmaceuticals, Inc. was 80.89%, occurring on Oct 16, 2023. The portfolio has not yet recovered.

The current Anebulo Pharmaceuticals, Inc. drawdown is 67.93%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-80.89%May 24, 2021604Oct 16, 2023
-1.41%May 10, 20217May 18, 20211May 19, 20218

Volatility

Volatility Chart

The current Anebulo Pharmaceuticals, Inc. volatility is 21.02%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%OctoberNovemberDecember2024FebruaryMarch
21.02%
2.80%
ANEB (Anebulo Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Anebulo Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items